144 related articles for article (PubMed ID: 9783591)
21. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
22. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
Goren MP
Med Pediatr Oncol; 2003 Sep; 41(3):186-9. PubMed ID: 12868117
[TBL] [Abstract][Full Text] [Related]
24. Future directions in gynecologic cancer.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
[TBL] [Abstract][Full Text] [Related]
25. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
26. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
Werner-Wasik M; Langer C; Movsas B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
[TBL] [Abstract][Full Text] [Related]
28. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Hartmann JT; Knop S; Fels LM; van Vangerow A; Stolte H; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Jan; 11(1):1-6. PubMed ID: 10757556
[TBL] [Abstract][Full Text] [Related]
29. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin and hypomagnesemia.
Lajer H; Daugaard G
Cancer Treat Rev; 1999 Feb; 25(1):47-58. PubMed ID: 10212589
[TBL] [Abstract][Full Text] [Related]
31. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
Cronin S; Uberti JP; Ayash LJ; Raith C; Ratanatharathorn V
Bone Marrow Transplant; 2000 Dec; 26(11):1247-9. PubMed ID: 11149742
[TBL] [Abstract][Full Text] [Related]
32. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
34. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
35. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
36. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
37. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
38. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.
Pujol JL; Carestia L; Daurès JP
Br J Cancer; 2000 Jul; 83(1):8-15. PubMed ID: 10883661
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
40. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
